

BLAU FARMACÊUTICA S.A.
CNPJ/ME No. 58.430.828/0001-60
NIRE No. 35.300.416.406 | CVM Code No. 2462-7
(Publicly Held Company)

**MINUTES OF THE BOARD OF DIRECTORS MEETING
HELD ON MARCH 17, 2026**

1. **Date, Time, and Location:** On the seventeenth day of March 2026, at 10:00 AM, at the headquarters of Blau Farmacêutica S.A. ("Company"), via videoconference among the members.
2. **Call and Attendance:** Notice was waived considering the attendance of all members. Present were the members of the Board of Directors:
 - Mr. Rodolfo Alfredo Gerardo Hahn Chairman of the Board;
 - Mr. Marcelo Rodolfo Hahn Vice Chairman of the Board;
 - Mr. Roberto Carlos de Campos Morais Regular Member;
 - Ms. Simone Petroni Agra Independent Member;
 - Dr. José Antônio Miguel Neto Independent Member;
 - Dr. Antonio Carlos Buzaid Independent Member;Invited by the Company:
 - Mr. Douglas Rodrigues Adm., Finan. Officer and IRO of the Company;
3. **Presiding Board:** Mr. Rodolfo Alfredo Gerardo Hahn assumed the chairmanship of the meeting, inviting me, Paulo Zaccharias Neto, to act as secretary, thus constituting the table.
4. **Agenda:** To deliberate on the Financial Statements and respective Explanatory Notes for the fiscal year ended December 31, 2025.
5. **Resolutions:** The members of the Board of Directors unanimously and without reservation resolved as follows:
 - 5.1. Analysis and resolution regarding the Management Report and Financial Statements for the period ended December 31, 2025: A presentation was made by Mr. Douglas Rodrigues, Administrative, Financial Officer and Investor Relations Officer of the Company, of the Management Report and Financial Statements for the fiscal year ended December 31, 2025.

After discussion, the members of the Board of Directors, in accordance with the favorable opinion of the Company's Audit and Ethics Committee at a meeting held on March 13, 2026, *recommended to the General Meeting of Shareholders the approval of the Independent Auditors' Report, issued without reservations, as well as recommended the approval of the Company's Financial Statements for the fiscal year ended December 31, 2025, accompanied by the Management Reports and the minutes of the Audit and Ethics Committee.*

Furthermore, the Executive Board of the Company was authorized to take all necessary measures for the disclosure of the Financial Statements for the year ended December 31, 2025 for subsequent resolution by the General Meeting of Shareholders of the Company.
6. **Drafting of the Minutes:** Approval of the drafting of the minutes in the form of a summary of the events occurred, as provided by Article 130, Paragraph 1, of the Brazilian Corporation Law.
7. **Documents filed at the Company's headquarters:** Minutes of the Audit and Ethics Committee meeting held on March 13, 2026, Auditor's Report, Financial Statements, and Explanatory Notes for the period ended December 31, 2025, which will remain filed at the Company's headquarters.
8. **Closure:** There being no further business, the proceedings were closed, and these minutes, read and duly approved, were signed by the Secretary and all attending members of the Board of Directors.

9. **Signatures:** Composition of the Presiding Board: Chairman – Mr. Rodolfo Alfredo Gerardo Hahn; Secretary – Mr. Paulo Zaccharias Neto. Board Members: Messrs. Rodolfo Alfredo Gerardo Hahn, Marcelo Rodolfo Hahn, Roberto Carlos de Campos Morais; Dr. José Antonio Miguel Neto, Dr. Antonio Carlos Buzaid, and Ms. Simone Petroni Agra.

Cotia, March 17, 2026

Presiding Board

Rodolfo Alfredo Gerardo Hahn
Chairman of the Table

Paulo Zaccharias Neto
Secretary

Attending Members

Rodolfo Alfredo Gerardo Hahn
Chairman

Marcelo Rodolfo Hahn
Vice Chairman

Roberto Carlos de Campos Morais
Regular Member

José Antônio Miguel Neto
Independent Member

Antonio Carlos Buzaid
Independent Member

Simone Petroni Agra
Independent Member